Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use.

A trend toward greater survival that did not reach statistical significance was seen for OC-k3 cells treated with 2 mM GM C1a (93.3% ± 5.9%; no significant loss of viability compared to controls; p > 0.1) compared to 2 mM GM (80.7% ± 0.8%; significant loss of viability compared to controls; p < 0.0001) (Fig. 1a ).

also in 111,027 other papers